toxylact: a07ax03 nifuroxazide

The first professional lActological database in the word

A07AX03 corresponds to nifuroxazide, an oral nitrofuran intestinal antibacterial used for acute infectious diarrhoea and colitis, designed to act locally in the gut with minimal systemic absorption. From a toxicological‑lactological standpoint, its very low oral bioavailability in adults and consequently low expected passage into breast milk support a favourable breastfeeding safety profile, although regulatory product information often remains cautious because of theoretical mutagenic concerns and limited direct lactation data.atcddd.fhi+6

ATC classification and group definition

Nifuroxazide is classified under ATC code A07AX03 within group A07 “Antidiarrheals, intestinal anti‑inflammatory/anti‑infective agents” and subgroup A07A “Intestinal antiinfectives”.wikipedia+2
The A07AX subgroup (“Other intestinal antiinfectives”) contains locally acting antiinfectives not falling into antibiotics (A07AA), sulfonamides (A07AB) or imidazole derivatives (A07AC).atcddd.fhi+1

The ATC/DDD Index lists nifuroxazide with a Defined Daily Dose (DDD) of 0.6 g by oral route (unit “g”, administration route “O”) for drug utilisation studies.iris.who+1
This DDD is a technical metric and may differ from actual prescribed doses, which are determined by product characteristics and clinical guidelines.iris.who

Pharmacodynamic properties

Nifuroxazide is a nitrofuran antibacterial that exerts broad‑spectrum activity against common enteropathogens such as Staphylococcus spp, Clostridium spp, Escherichia coli, Salmonella spp and others implicated in bacterial diarrhoea.ingentaconnect+1
Within bacterial cells, it is metabolised to reactive nitro intermediates that interfere with enzyme systems involved in nucleic acid and protein synthesis, leading to impaired cellular function and bacterial cell death.synapse.patsnap+1

The drug’s activity is largely confined to the intestinal lumen, where it reduces bacterial load and toxin production, thereby improving diarrhoeal symptoms and limiting local inflammation.sciencedirect+2
Recent pharmacological reviews also describe additional experimental properties (anticancer, antioxidant, anti‑inflammatory effects), but these are not part of established clinical use for acute diarrhoea.sciencedirect

Therapeutic indications and clinical use

Clinically, nifuroxazide is indicated for acute infectious diarrhoea and other susceptible gastrointestinal infections, including traveller’s diarrhoea and colitis of bacterial origin.drugbank+2
It is often prescribed from the onset of diarrhoea without waiting for stool culture results, reflecting its local action and broad coverage of likely bacterial pathogens.chemicalbook

Open clinical trials have shown that orally administered nifuroxazide can be more effective than probiotics in treating acute diarrhoea, with similar safety profiles.pmc.ncbi.nlm.nih
Because it acts within the gut and is poorly absorbed, it is not used for systemic infections; systemic antibiotics are preferred when invasive disease is suspected.atcddd.fhi+1

Dosage, DDD and administration

The ATC/DDD index specifies a DDD of 0.6 g nifuroxazide orally, used primarily for comparisons of drug utilisation across populations.atcddd.fhi+1
In practice, adult dosing commonly involves divided doses (for example 200 mg three times daily), with total daily doses around or somewhat close to the DDD, depending on national product information and formulation strength.chemicalbook+1

Tablets or oral suspensions are used, with treatment durations usually limited to a few days until resolution of symptoms.sciencedirect+1
Prolonged use is generally not recommended, both because acute diarrhoea should resolve and to minimise unnecessary exposure to nitrofuran compounds.ema.europa+1

Pharmacokinetics and systemic exposure

Nifuroxazide has very low oral bioavailability due to low or almost zero intestinal absorption, so most of the dose remains in the gastrointestinal lumen and is excreted in the faeces.e-lactation+1
This pharmacokinetic profile results in low maternal plasma concentrations, which in turn limit systemic exposure and potential transfer into breast milk.e-lactation+1

Because of its poor absorption, even drug that might reach breast milk would face low oral bioavailability in the infant, further reducing systemic infant exposure, except possibly in premature neonates with higher intestinal permeability.medsafe+1
Regulatory documents note that it is not known whether nifuroxazide is excreted into human milk, but agree that any amount is likely to be low given its pharmacokinetics.scribd+1

Toxicological profile in adults

In adults, nifuroxazide is generally well tolerated, with adverse effects mostly limited to mild gastrointestinal symptoms (nausea, abdominal pain) and occasional hypersensitivity reactions such as rash or pruritus.pmc.ncbi.nlm.nih+2
Because of minimal systemic absorption, serious systemic toxicity is uncommon compared with fully absorbed nitrofurans; however, nitrofuran‑class concerns about possible mutagenic or carcinogenic potential underlie regulatory caution for long‑term use.scribd+1

Modern reviews highlight that nifuroxazide has been used for decades as an effective therapy for acute diarrhoea with a good safety record when limited to short courses.chemicalbook+1
Product information in some jurisdictions has been updated to advise against use in pregnancy and breastfeeding mainly on theoretical grounds, not on documented human toxicity.scribd

Lactational safety and infant risk

Lactation‑specific resources report that nifuroxazide has very low oral bioavailability with low or zero intestinal absorption, making passage into breast milk unlikely or minimal.e-lactation
Because any small amount in milk would then face low oral bioavailability in the infant, clinically relevant infant plasma levels are improbable, except possibly in premature babies or the immediate neonatal period with higher gut permeability.medsafe+1

On this basis, one expert database classifies nifuroxazide as “Very Low Risk – Compatible. Not risky for breastfeeding or infant”, while still advising routine infant follow‑up.e-lactation
General breastfeeding guidance notes that medicines excreted into milk at less than 10% of the maternal dose are usually considered compatible, especially when they also have low oral availability in the infant.pmc.ncbi.nlm.nih+1

At the same time, some regulatory assessments emphasise theoretical mutagenic potential of nitrofuran derivatives and recommend avoiding nifuroxazide in pregnancy and breastfeeding as a precaution, despite low expected exposure.ema.europa+1
Thus, lactational risk assessments may differ: pharmacokinetic‑based sources tend to view it as compatible, while regulatory labelling is more conservative due to class effects and limited direct data.ema.europa+2

Clinical recommendations for breastfeeding women

For a breastfeeding woman with acute infectious diarrhoea, nifuroxazide can be considered a low‑risk option when a locally acting intestinal antibacterial is appropriate, particularly given its low absorption and low expected milk transfer.sciencedirect+1
However, clinicians should weigh this against regulatory precautionary statements and, where possible, consider whether non‑antibacterial measures (rehydration, symptomatic care) or well‑studied systemic antibiotics compatible with breastfeeding might suffice.breastfeedingnetwork+2

If nifuroxazide is prescribed during lactation, use should be limited to short courses at standard doses, while monitoring the infant for non‑specific gastrointestinal effects (changes in stool pattern, vomiting) or hypersensitivity, which are unlikely but possible.medsafe+2
Special caution is warranted in premature or very young neonates, where intestinal permeability is higher; in such cases, individualised assessment may favour alternative treatments or closer monitoring.pmc.ncbi.nlm.nih+1

Counselling should explain that available pharmacokinetic and expert data suggest minimal infant exposure and low risk, yet regulatory agencies maintain caution mainly for theoretical reasons.scribd+2
As with all medicines in lactation, the general principles of using the lowest effective dose for the shortest duration and avoiding unnecessary polypharmacy apply.pmc.ncbi.nlm.nih+1

Educational summary for practice

A07AX03 nifuroxazide is a locally acting nitrofuran intestinal antibacterial with a DDD of 0.6 g orally, widely used for acute bacterial diarrhoea and related gastrointestinal infections.wikipedia+3
Its very low oral bioavailability, low systemic absorption, and consequently low expected passage into breast milk underpin a favourable toxicological‑lactological profile, although conservative product information reflects theoretical mutagenicity concerns rather than documented breastfeeding harm.ema.europa+2

In toxicological‑lactological practice, nifuroxazide can generally be regarded as compatible with breastfeeding for short‑term use, especially when guided by careful clinical judgement and infant monitoring.pmc.ncbi.nlm.nih+2
Healthcare professionals should integrate ATC classification, pharmacology, pharmacokinetics, and regulatory guidance to provide nuanced, evidence‑based counselling to breastfeeding mothers requiring treatment for acute infectious diarrhoea.sciencedirect+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.